Sinovac receives conditional marketing authorization in China for its COVID-19 vaccine

Sinovac Biotech Ltd. (NASDAQ:SVA) ("Sinovac" or the "Company"), a leading provider of biopharmaceutical products in China, announced that the China National Medical Products Administration (NMPA) has granted a conditional marketing authorization (CMA) to Sinovac for CoronaVac, Sinovac’s COVID-19 vaccine in individuals aged 18 and above.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Business Business and Industry Source Type: news